Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first …
TE Hutson, FX Liu, C Dieyi, R Kim, S Krulewicz… - Journal of Managed …, 2021 - jmcp.org
BACKGROUND: A key therapeutic goal of metastatic renal cell carcinoma (mRCC) treatment
is delayed disease progression. The degree to which early therapeutic success affects …
is delayed disease progression. The degree to which early therapeutic success affects …
Long-term response to first-line Pazopanib therapy in mRCC patients: a multicenter Italian experience
A Sbrana, E Biasco, F Paolieri, E Palesandro… - Anticancer …, 2018 - ar.iiarjournals.org
Background/Aim: The specific characteristics of patients who are most likely to benefit from
pazopanib therapy are still uncertain. We report on the results of an Italian multicenter …
pazopanib therapy are still uncertain. We report on the results of an Italian multicenter …
Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma
DS Chun - 2021 - search.proquest.com
The rapid influx of new treatment options for metastatic renal cell carcinoma (mRCC) pose
unique challenges in clinical practice, as therapies are orally administered in the home …
unique challenges in clinical practice, as therapies are orally administered in the home …
What is already known about this subject
A Bhanegaonkar - Visit NephU. org, 2021 - jmcp.org
ABSTRACT BACKGROUND: A key therapeutic goal of metastatic renal cell carcinoma
(mRCC) treatment is delayed disease progression. The degree to which early therapeutic …
(mRCC) treatment is delayed disease progression. The degree to which early therapeutic …